Minivelle Film, Extended Release
Product Images NDC 68968-6650
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Minivelle (NDC 68968-6650). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Noven Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure D (Minivelle Figure 10)
Figures E And F (Minivelle Figure 11)
Figure G (Minivelle Figure 12)
Trade Carton 0.025mg (Minivelle Figure 13)
Carton 0.0375mg (Minivelle Figure 14)
Carton 0.05mg (Minivelle Figure 15)
Carton 0.075mg (Minivelle Figure 16)
Minivelle is a transdermal system that contains 1.24 mg of estradiol USP, which delivers 0.075 mg/day. The system should be applied twice-weekly and contains an acrylic adhesive, silicone adhesive, and other inactive ingredients. It should be stored at 20°C to 25°C and should only be used transdermally. The package should be kept out of children's reach, and applied immediately after removing it from the pouch. Dosage and administration instructions can be found in the package insert. The manufacturer is Noven Pharmaceuticals, Inc. and the distributor is Noven Therapoutics, LLC, both located in Miami, Florida.*
Carton 0.1mg (Minivelle Figure 17)
This appears to be a product description for Minivelle, a transdermal system that delivers 0.1mg/day of estradiol USP. It comes in a package containing 8 systems and is applied twice-weekly. The product contains acrylic and silicone adhesive, oleyl alcohol, dipropylene glycol, among other inactive components. Package should be kept out of reach of children and stored at a controlled room temperature. The manufacturer is Noven Pharmaceuticals, Inc, and the distributor is Noven Therapoutics, LLC from Miami, Florida.*
Layers Of Minivelle (Minivelle Figure 2)
Figure 1: Mean Baseline-uncorrected Estradiol Serum Concentration-time Profiles Following A Single Dose Of Minivelle 0.1 mg Per Day (treatment A), 0.05 mg Per Day (treatment B), And 0.025 mg Per Day ( (Minivelle Figure 3)
Figure 2: Mean (sd) Change From Baseline In Mean Daily Number Of Hot Flushes For Vivelle 0.0375 mg Versus Placebo In A 12 Week Trial. (Minivelle Figure 4)
The text describes statistical data of a study conducted over 12 weeks, with measurements taken at weeks 4, 8, and 12. The data includes numeric values for different variables and a comparison between a treatment called Vivelle and a placebo. The last sentence suggests that there was a statistically significant difference between the two treatments.*
Figure 3: Bone Mineral Density – Ap Lumbar Spine (Minivelle Figure 5)
Figure 4 Bone Mineral Density (Femoral neck)
This text appears to be a table showing the percentage change from baseline for various treatments over the course of several weeks. The treatments are labeled A, B, C, D, and P. There are statistical values listed with some of the treatments, including p-values. The full extent of this data set is not available and any further interpretation of the data is not possible.*
Figure A (Minivelle Figure 7)
Figure B (Minivelle Figure 8)
Figure C (Minivelle Figure 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.